Skip to main content
TipRanks
Go Ultimate75% OFF

Cartesian Therapeutics (RNAC) Stock Statistics & Valuation Metrics

1,213 Followers

Total Valuation

Cartesian Therapeutics has a market cap or net worth of $193.69M. The enterprise value is $155.89M.

Market Cap
$193.69M
Enterprise Value
$155.89M

Share Statistics

Cartesian Therapeutics has 30,503,004 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
30,503,004
Owned by Insiders
42.55%
Owned by Institutions
15.57%

Financial Efficiency

Cartesian Therapeutics’s return on equity (ROE) is 1.03 and return on invested capital (ROIC) is -28.36%.

Return on Equity (ROE)
1.03
Return on Assets (ROA)
-0.44
Return on Invested Capital (ROIC)
-28.36%
Return on Capital Employed (ROCE)
-0.31
Revenue Per Employee
37.29K
Profits Per Employee
-1.74M
Employee Count
75
Asset Turnover
0.01
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Cartesian Therapeutics is -1.29. Cartesian Therapeutics’s PEG ratio is 0.01.

PE Ratio
-1.29
PS Ratio
188.97
PB Ratio
-1.48
Price to FCF
-2.17
Price to Operating Cash Flow
-2.18
PEG Ratio
0.01

Income Statement

In the last 12 months, Cartesian Therapeutics had revenue of 2.80M and earned -130.30M in profits. Earnings per share was -5.02.

Revenue
2.80M
Gross Profit
2.80M
Operating Income
-86.70M
Pretax Income
-139.50M
Net Income
-130.30M
EBITDA
-136.54M
Earnings Per Share (EPS)
-5.02

Cash Flow

In the last 12 months, operating cash flow was -88.20M and capital expenditures -1.23M, giving a free cash flow of -89.44M billion.

Operating Cash Flow
-88.20M
Free Cash Flow
-89.44M
Free Cash Flow per Share
-2.95

Dividends & Yields

Cartesian Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-46.17%
Earnings Yield
-67.29%

Stock Price Statistics

Beta
2.54
52-Week Price Change
-12.17%
50-Day Moving Average
7.14
200-Day Moving Average
7.64
Relative Strength Index (RSI)
42.20
Average Volume (3m)
137.54K

Important Dates

Cartesian Therapeutics upcoming earnings date is Mar 17, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Mar 17, 2027
Ex-Dividend Date
―

Financial Position

Cartesian Therapeutics as a current ratio of 8.65, with Debt / Equity ratio of -10.04%

Current Ratio
8.65
Quick Ratio
8.65
Debt to Market Cap
0.02
Net Debt to EBITDA
0.82
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Cartesian Therapeutics has paid -9.19M in taxes.

Income Tax
-9.19M
Effective Tax Rate
0.07

Enterprise Valuation

Cartesian Therapeutics EV to EBITDA ratio is -1.00, with an EV/FCF ratio of -1.47.

EV to Sales
127.86
EV to EBITDA
-1.00
EV to Free Cash Flow
-1.47
EV to Operating Cash Flow
-1.49

Balance Sheet

Cartesian Therapeutics has $122.97M in cash and marketable securities with $60.34M in debt, giving a net cash position of $62.64M billion.

Cash & Marketable Securities
$122.97M
Total Debt
$60.34M
Net Cash
$62.64M
Net Cash Per Share
$2.05
Tangible Book Value Per Share
-$8.99

Margins

Gross margin is 100.00%, with operating margin of -10009.17%, and net profit margin of -12635.12%.

Gross Margin
100.00%
Operating Margin
-10009.17%
Pretax Margin
-13332.10%
Net Profit Margin
-12635.12%
EBITDA Margin
-12759.12%
EBIT Margin
-13054.73%

Analyst Forecast

The average price target for Cartesian Therapeutics is $36.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$36.75
Price Target Upside
478.74% Upside
Analyst Consensus
Strong Buy
Analyst Count
4
Revenue Growth Forecast
―
EPS Growth Forecast
―

Scores

Smart Score
10
AI Score
47